Michael Wolff Jensen

Algemeen Adviseur bij ASCENDIS PHARMA A/S

Vermogen: 264 412 $ op 30-04-2024

53 jaar

Connecties 92

Health Technology

Utilities

Consumer Services

Momenteel actieve connecties

Naam	Geslacht	Leeftijd	Verwante bedrijven	Samenwerking
Jan Mikkelsen	M	65	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S Ascendis Pharma Endocrinology Division A/S Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. Ascendis Pharma Bone Diseases A/S Ascendis Pharma Growth Disorders AS VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	22 jaar
Lotte Sønderbjerg	F	62	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	21 jaar
An Bang Lu	M	58	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 jaar
Albert Cha	M	51	ASCENDIS PHARMA A/S	10 jaar
Peter Rasmussen	M	55	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	12 jaar
Lisa Bright	F	56	ASCENDIS PHARMA A/S	7 jaar
Yi Bo Cao	M	42	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction.	3 jaar
Dan Dan Dong	M	40	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 jaar
Kennett Sprogøe	M	46	ASCENDIS PHARMA A/S	17 jaar
Rasmus Errboe	M	45	ORSTED A/S	12 jaar
William Fairey	M	60	ASCENDIS PHARMA A/S	2 jaar
Scott Smith	M	50	ASCENDIS PHARMA A/S	8 jaar
Martine van Vugt	M	71	GENMAB A/S	23 jaar
Lars Holtug	M	66	ASCENDIS PHARMA A/S	6 jaar
Pierre Armand Morgon	M	61	EUROCINE VACCINES AB	11 jaar
Carl-Johan Dalsgaard	M	68	Vicore Pharma AB Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden.	-
Hong Ni	F	52	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 jaar
Peng Kuan Chan	M	60	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 jaar
Zheng Bin Yao	M	58	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 jaar
Siham Imani	F	47	ASCENDIS PHARMA A/S	2 jaar
Shan Fu	M	56	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 jaar
Heidi Hunter	F	66	VICORE PHARMA HOLDING AB	4 jaar
Jan Nils Sandström	M	86	EUROCINE VACCINES AB	12 jaar
Melinda Baker	F	-	ASCENDIS PHARMA A/S	-
Hans Jeppsson	M	-	Vicore Pharma AB Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden.	-
Sze Ting Chan	F	42	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	-
Elin Rosendahl	F	-	VICORE PHARMA HOLDING AB	4 jaar
Birgitte Stephensen	F	63	GENMAB A/S	22 jaar
Tim Lee	M	-	ASCENDIS PHARMA A/S	-
Anni Lotte Kirstine Pedersen	F	-	Ascendis Pharma Endocrinology Division A/S Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark.	12 jaar
Jessica Shull	M	-	VICORE PHARMA HOLDING AB	3 jaar
Stina Singel	M	50	ASCENDIS PHARMA A/S	4 jaar
Maha Katabi	M	50	Ascendis Pharma, Inc.	-
Jun Yang	M	52	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	4 jaar
Jun Chen	M	54	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 jaar
Flemming Steen Jensen	M	63	ASCENDIS PHARMA A/S	9 jaar

Meer zien

Relatiegrafiek

Connectie in verschillende bedrijven

Oude connecties

Naam	Geslacht	Leeftijd	Verwante bedrijven	Samenwerking
Rafaèle Elisabeth Tordjman	M	54	ASCENDIS PHARMA A/S	13 jaar
Thomas Soloway	M	55	ASCENDIS PHARMA A/S	5 jaar
Birgitte Volck	M	61	ASCENDIS PHARMA A/S	7 jaar
Michael Blair Widmer	M	76	GENMAB A/S	11 jaar
Benny Dalgaard Loft	M	59	ORSTED A/S	7 jaar
Anja Leschly	F	52	VELOXIS PHARMACEUTICALS A/S	-
Tom Vink	M	61	GENMAB A/S	-
Henrik Poulsen	M	57	ORSTED A/S	8 jaar
Martin Olin	M	55	ASCENDIS PHARMA A/S	4 jaar
Peter Schøtt Knudsen	M	51	VELOXIS PHARMACEUTICALS A/S	-
Michael Beckert	M	-	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	12 jaar
Carsten Krogsgaard Thomsen	M	67	ORSTED A/S	11 jaar
Bo Kruse	M	52	GENMAB A/S	8 jaar
Pia Gjellerup	F	65	ORSTED A/S	7 jaar
Jonathan Silverstein	M	57	ASCENDIS PHARMA A/S	-
James Healy	M	59	ASCENDIS PHARMA A/S	8 jaar
Thomas Dyrberg	M	69	VELOXIS PHARMACEUTICALS A/S	13 jaar
Kurt Anker Nielsen	M	78	VELOXIS PHARMACEUTICALS A/S	7 jaar
Karsten Havkrog Pedersen	M	74	GENMAB A/S	11 jaar
Thomas A. Larson	M	62	ASCENDIS PHARMA A/S	-
Kathrine Westermann	F	-	ORSTED A/S	-
Rasmus Nagel	M	-	ORSTED A/S	3 jaar
Rikke Glahn Ren	F	-	GENMAB A/S	-
Dana Pizzuti	M	69	ASCENDIS PHARMA A/S	2 jaar
Daniel Muthmann	M	-	ORSTED A/S	-
Jorgen Petersen	M	-	GENMAB A/S	-
Marie Olliver	M	-	EUROCINE VACCINES AB	-
Patrick van Berkel	M	55	GENMAB A/S	9 jaar
Christina Aabo	F	-	ORSTED A/S	10 jaar
Breian Knudsen	M	-	VELOXIS PHARMACEUTICALS A/S	9 jaar
Mark Bach	M	67	ASCENDIS PHARMA A/S	-
Rune Róin	M	-	ORSTED A/S	-
Tomas Lykke Nielsen	M	-	ORSTED A/S	-
Sigurd Okkels	M	-	ASCENDIS PHARMA A/S	4 jaar
Christian Skakkebæk	M	-	ORSTED A/S	10 jaar
Gérard Soula	M	78	VELOXIS PHARMACEUTICALS A/S	-
Grethe Nørskov Rasmussen	M	62	ASCENDIS PHARMA A/S	11 jaar
Jytte Koed Madsen	F	71	ORSTED A/S	-
Anders Eldrup	M	76	ORSTED A/S	11 jaar
Jean Deleage	M	83	VELOXIS PHARMACEUTICALS A/S	-
Lars Rebien Sørensen	M	69	ORSTED A/S	5 jaar
Martin Auster	M	49	ASCENDIS PHARMA A/S	2 jaar
Mark Brennan	M	61	ASCENDIS PHARMA A/S	-
Torben Nissen	M	53	ASCENDIS PHARMA A/S	3 jaar
Edwin de Graaf	M	-	ASCENDIS PHARMA A/S	-
Francesca DeMartino	F	-	VELOXIS PHARMACEUTICALS A/S	-
Jens Kampmann	M	86	ORSTED A/S	7 jaar
Thomas Dalsgaard	M	58	ORSTED A/S	3 jaar
Joseph Fred Yospe	M	66	GENMAB A/S	2 jaar
Paul W. H. I. Parren	M	60	GENMAB A/S	16 jaar
Lena Birgitta Degling Wikingsson	M	61	EUROCINE VACCINES AB	4 jaar
Jonathan Leff	M	66	ASCENDIS PHARMA A/S	3 jaar
Jesper Høiland	M	63	ASCENDIS PHARMA A/S	2 jaar
Neil Ringdahl	M	-	ASCENDIS PHARMA A/S	-
Karsten Anker Petersen	M	53	ORSTED A/S	-
Niels Svenstrup	M	54	ASCENDIS PHARMA A/S	2 jaar

Statistieken

Land	Connecties	% van het totaal
Denemarken	72	78.26%
China	11	11.96%
Zweden	9	9.78%
Verenigde Staten	1	1.09%

Ouderdom van de connecties

Actief

Verleden

Man

Vrouw

Besturend

Uitvoerend

Oorsprong van de connecties